SUMMARY A 64-year-old woman presented with diffuse and numerous pigmented macules on her face and upper back. Histopathological examination of a skin punch biopsy of the rash showed a lichenoid dermatitis. The most likely offending drug was pravastatin. Cessation of pravastatin resulted in gradual fading of the pigmentation. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors have previously been reported to cause lichenoid drug eruptions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1440-0960.2006.00225.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Novel Presentation of Lichenoid Dermatoses Preceding Bullous Pemphigoid Secondary to Immune Checkpoint Inhibitor Therapy.
Skinmed
January 2025
Department of Dermatology, Medical Center, Bronx, NY;
The 73-year-old non-Hispanic, African-American man with a history of renal cell carcinoma (RCC), status post-nephrectomy receiving Lenvatinib, and metastatic disease, for which he also had received nivolumab for 13½ months. An itchy eruption appeared one month after the discontinuation of nivolumab and after the beginning of axitinib therapy. Physical examination revealed pink-violaceous scaly plaques, some with trailing scales on the anterior aspect of the trunk (Figure 1), a slight erosion on the hard palate, and hypopigmentation on the hands and legs.
View Article and Find Full Text PDFLichenoid Drug Eruption Secondary to Apalutamide Treatment.
Cutis
October 2024
Madelyn M. Class is from the Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania. Drs. McCoy, Hafeez, and Westheim are from the Department of Dermatology, St. Luke's University Health Network, Easton, Pennsylvania.
A case of probable drug-induced psoriasis to dapagliflozin.
SAGE Open Med Case Rep
November 2024
Division of Dermatology, Faculty of Medicine, Memorial University of Newfoundland, St. John's, NL, Canada.
Exposure to certain drugs can trigger new-onset psoriasis or flaring of existing psoriatic disease. The clinical presentation of drug-induced psoriasis can vary, and although there are features suggestive of drug-induced psoriasis, there are currently no standardized criteria to differentiate it from conventional psoriasis. Patients may present with localized psoriasiform plaques, or variants such as palmoplantar, nail disease, or widespread erythroderma.
View Article and Find Full Text PDFCutaneous Toxicities of Advanced Treatment for Cutaneous Melanoma: A Prospective Study from a Single-Center Institution.
Cancers (Basel)
October 2024
Oncologic Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
Article Synopsis
- Advanced melanoma treatments have evolved with targeted therapies and immunotherapies, which significantly impact management but also lead to increased skin toxicities during treatment.
- A study in Bologna identified that 37.5% of 202 patients treated for melanoma developed cutaneous adverse events, primarily linked to drugs like ipilimumab and nivolumab.
- Most skin reactions were low-grade and manageable, but some resulted in severe conditions, highlighting the importance of recognizing and treating these toxicities to ensure patient quality of life.
Concurrent Eruptive Melanocytic Nevi and Multiple Keratoacanthomas Induced by Encorafenib.
Cureus
September 2024
Oncology, Biokliniki Athinon, Athens, GRC.
Article Synopsis
- - A case study discusses a 64-year-old male with metastatic colorectal cancer who developed severe itching and new skin lesions after treatment with encorafenib and panitumumab, medications targeting cancer pathways.
- - The patient showed a mix of skin lesions, including benign moles and keratoacanthomas, with further evaluation confirming a link between the skin reactions and the use of encorafenib, as validated by the Naranjo scale.
- - Stopping the medications led to significant improvement in skin lesions, highlighting the importance of ongoing skin assessments for patients on BRAF inhibitors to manage side effects effectively.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!